← Leaderboards
Charles Erlichman
Mayo Clinic Coll Of Medicine, Rochester
$15,466,165
Attributed
$15,746,164
Total exposure
11
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2005–14$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$15,746,164 · 11
By mechanism
U01$8,165,346 · 1
N01$6,084,176 · 3
R01$707,328 · 1
UM1$559,998 · 1
U10$157,740 · 1
M01$71,576 · 4
Top collaborators
- Paul Haluska1 shared
Most similar at Mayo Clinic Coll Of Medicine, Rochester
Same institution · by research overlap
- Charles L Loprinzi$16,465,874
- Jan C Buckner$13,181,861
- Alex A Adjei$13,436,633
- Edith A Perez$1,891,637
- Thomas E. Witzig$5,636,824
Others in their field
Top investigators on “Pharmacogenetics”
- Richard L Schilsky · University Of Chicago$84,553,000
- Monica M Bertagnolli · Strang Cancer Prevention Center$61,393,123
- Russ Biagio Altman · University Of California San Francisco$42,267,633
- Richard M Weinshilboum · Mayo Clinic Coll Of Medicine, Rochester$40,766,671
- Dan M Roden · Vanderbilt University Medical Center$40,676,144
- Scott T Weiss · University Of California, San Diego$39,481,472
Research focus
PharmacogeneticsScheduleNew AgentsDrug KineticsBaseDoseNational Cancer InstituteNeoplasm /Cancer ChemotherapyToxic EffectDna Repair PathwayLaboratoriesAffectApoptosis RegulatorDrug CombinationsMaximum Tolerated DoseEnzymesBiological ModelsEvaluationMonitorChemotherapyDrug ToxicityClinical EffectBiologicalBiochemical Pathway
Grant awards (32)
NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis$559,998
UM1 · FY2014 · CA
Phase I Clinical Trials of Anticancer Agents$874,586
U01 · FY2013 · CA · contact PI
Phase I Clinical Trials of Anticancer Agents$875,307
U01 · FY2012 · CA · contact PI
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS$940,202
N01 · FY2011 · CA · contact PI
Phase I Clinical Trials of Anticancer Agents$879,674
U01 · FY2011 · CA · contact PI
Early Therapeutics Development with Phase II Emphasis$657,491
N01 · FY2011 · CA · contact PI
Phase I Clinical Trials of Anticancer Agents$16,177
U01 · FY2011 · CA · contact PI
Phase I Clinical Trials of Anticancer Agents$911,511
U01 · FY2010 · CA · contact PI
Early Therapeutics Development with Phase II Emphasis$644,598
N01 · FY2010 · CA · contact PI
Phase I Clinical Trials of Anticancer Agents$28,078
U01 · FY2010 · CA · contact PI
Early Therapeutics Development with Phase II Emphasis$2,053,128
N01 · FY2009 · CA · contact PI
Phase I Clinical Trials of Anticancer Agents$910,222
U01 · FY2009 · CA · contact PI
TAS:: 75 0850 ::TAS RECOVERY ACT - ACTNOW CLINICAL TRIAL 8288$499,997
N01 · FY2009 · CA · contact PI
Phase I Clinical Trials of Anticancer Agents$886,532
U01 · FY2008 · CA · contact PI
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS$1,288,760
N01 · FY2007 · CA · contact PI
Phase I Clinical Trials of Anticancer Agents$626,936
U01 · FY2007 · CA · contact PI
Phase I Clinical Trials of Anticancer Agents$676,691
U01 · FY2006 · CA · contact PI
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS-261622005$0
N01 · FY2006 · CM · contact PI
GEMCITABINE, 17-ALLYLAMINOGELDANAMYCIN (17-AAG) AND CISPLATIN$18,007
M01 · FY2005 · RR
PHASE I TRIAL OF 17-ALLYLAMINOGELDANAMYCIN IN SOLID TUMOR PATIENTS$1,658
M01 · FY2005 · RR
Biochemical Effects of Disrupting HSP90$225,059
R01 · FY2004 · CA
Phase I Trial of 17-Allylaminogeldanamycin in Solid Tumor Patients$25,724
M01 · FY2004 · RR
A Phase I Trial of Gemcitabine, 17-AAG, and Cisplatin$20,625
M01 · FY2004 · RR
2-Methoxyestradiol in Patients with Advanced Solid Tumor$5,562
M01 · FY2004 · RR
Biochemical Effects of Disrupting HSP90$225,059
R01 · FY2003 · CA
PHASE I CLINICAL TRIALS OF ANTICANCER AGENTS$561,083
U01 · FY2002 · CA
Biochemical Effects of Disrupting HSP90$257,210
R01 · FY2002 · CA
NOVEL THERAPEUTICS$78,870
U10 · FY2002 · CA
NOVEL THERAPEUTICS$78,870
U10 · FY2002 · CA
PHASE I CLINICAL TRIALS OF ANTICANCER AGENTS$527,831
U01 · FY2001 · CA
NOVEL THERAPEUTICS$0
U10 · FY2001 · CA
PHASE I CLINICAL TRIALS OF ANTICANCER AGENTS$390,718
U01 · FY2000 · CA